ClinicalTrials.gov
ClinicalTrials.gov Menu

Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis (CAMPATH-1H)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01639573
Recruitment Status : Recruiting
First Posted : July 12, 2012
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Andreas Reiff MD, Children's Hospital Los Angeles

Brief Summary:
This phase I/II pilot trial seeks to demonstrate that prolonged administration of Campath-1H without prior marrow or stem cell harvesting can result in immunoablation similar to that achieved by hematopoietic stem cell transplantation (HSCT) from either bone marrow or peripheral blood stem cell sources in children and adolescents with severe treatment refractory systemic sclerosis (SSc).

Condition or disease Intervention/treatment
Scleroderma Drug: Campath

Detailed Description:

Patients, 8 to18 years of age, will be included if they have a proven diagnosis of diffuse cutaneous or systemic SSc as defined by the ACR criteria with evidence of active inflammatory disease Plus at least 1 of the following:SSc-related pulmonary disease with forced vital capacity (FVC) or hemoglobin-adjusted DLCO < 70% and evidence of alveolitis by high-resolution CT scan or bronchoalveolar lavage.

OR:History of SSc-related renal crisis or disease, not active at the time of screening

OR:Moderate to severe upper and/or lower gastrointestinal involvement

AND:Unacceptable toxicity or steroid dependence > 0.3 mg/kg/d,

OR:Failure to respond to, or unacceptable toxicity of MTX > 1mg/kg in combination with cyclosporine or azathioprine or cyclophosphamide 2 kg/d or Rituximab 375 mg/m2 x 4 doses or Imatinib 800 mg/

OR:Disease recurrence after tapering medication above


Study Type : Observational
Estimated Enrollment : 3 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Campath-1h as Immunoablative Therapy for Children and Adolescents With Treatment Refractory Systemic Sclerosis
Study Start Date : April 2011
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma
Drug Information available for: Alemtuzumab


Intervention Details:
  • Drug: Campath
    Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.


Primary Outcome Measures :
  1. Primary outcome [ Time Frame: 2 years ]
    To determine why the extended administration of Campath-1H results in immune ablation in some patients and immunosuppression in others, Number of Participants with Adverse Events as a Measure of Safety and Tolerability Campath-1H antibody levels during and after the completion of the Campath administration. (47) Thus, both the peak Campath-1H levels as well as the duration of circulating Campath will be determined.

  2. Campath [ Time Frame: The site will follow patients for 6 months post adverse event. ]
    Number of Participants with Adverse Events as a Measure of Safety and Tolerability



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients, 8 to18 years of age, will be included if they have a proven diagnosis of diffuse cutaneous or systemic SSc as defined by the ACR criteria with evidence of active inflammatory disease
Criteria

4.2 Inclusion/Exclusion criteria 4.2.1 Inclusion criteria

  • 8 to 21 years of age, inclusive
  • Diffuse, cutaneous dcSSc as defined by the ACR criteria with evidence of active inflammatory disease.
  • Plus at least 1 of the following:

    • dcSSc-related pulmonary disease with forced vital capacity (FVC) or hemoglobin-adjusted DLCO < 70% and evidence of alveolitis by high-resolution CT scan or bronchoalveolar lavage

OR

o History of SSc-related renal crisis or disease, not active at the time of screening

OR

  • Moderate to severe upper and/or lower gastrointestinal involvement AND
  • Unacceptable toxicity or steroid dependence > 0.3 mg/kg/d
  • Failure to respond to, or unacceptable toxicity of MTX > 1mg/kg in combination with cyclosporine or azathioprine or cyclophosphamide or Rituximab 375 mg/m2 x 4 doses or Imatinib 800 mg/d or tocilizumab 8 mg/kg for at least 3 doses.
  • Disease recurrence after tapering medication above (in #4)

4.2.2 Exclusion Criteria

  • Pulmonary, cardiac, hepatic, or renal impairment that would limit therapy and compromise survival includes, but is not restricted to, any of the following:

    • Severe pulmonary dysfunction: hemoglobin-corrected DLCO < 45%, DLCO <4 mL/mmHg/min/L or pO2 < 70 mm Hg or pCO2, ≥ 45 mm Hg without supplemental O2 sat 92% at rest without supplemental O2
    • Significant pulmonary hypertension
    • Uncontrolled clinically significant arrhythmias
    • NYHA heart failure class IV
    • LVEF < 50% by echo or prior insertion of a pacemaker or cardioverter-defibrillator
    • End-stage renal disease (GFR<50 ml/min/1.73 m2 or creatinine . 2 mg/dl; estimated CrCl < 40 mL/min or active, untreated dcSSc renal crisis at time of enrollment
    • Active hepatitis (ALT, AST, or bilirubin > 2x ULN)
  • Active gastric antral vascular ectasia (GAVE, "watermelon stomach")
  • 2 mg/kg/day prednisone or equivalent within 30 days of treatment
  • Unwilling or unable to discontinue DMARDs for treatment of dcSSc
  • Co-morbid illnesses with an estimated median life expectancy < 5 Years
  • Active uncontrolled infection
  • Positive serology for hepatitis B or C, HIV
  • ANC < 1500 cells/µL, platelets < 120,000 cells/µL, Hct < 27% or Hgb < 9.0 g/dL
  • Malignancy within the previous 2 years, excluding treated skin cancer
  • Myelodysplasia
  • Uncontrolled hypertension
  • History of hypersensitivity to murine or E. coli proteins
  • Pregnancy or unwilling to use contraceptive methods for at least 15 months
  • Steroid dependence: > 2mg/kg/day, prednisone or equivalent within 30 days prior to treatment
  • History of substance abuse within the last 5 years
  • History or presence of 2nd autoimmune disease requiring immunosuppressive therapy that has a substantial risk of recurrence
  • Demonstrated lack of compliance with prior medical care
  • Lack of rehabilitation potential

4.3 SSc patients, who fulfill the inclusion criteria, will then be assessed for residual thymic function since our previous study of pediatric dcSSc patients demonstrated that the dcSSc patients had decreased thymic function as compared to age matched controls as measured by the proportion of naïve CD4+ T lymphocytes (CD4+, CD31+), recent thymic emigrants (RTE). (5) Patients with less than 40% RTE will be excluded because of concerns about their ability to reconstitute their immune system after immune ablation.

4.4 dcSSc patients, who fulfill the screening criteria, will be consented for entry into the clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01639573


Locations
United States, California
Childrens Hospitla Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Andreas O Reiff, MD    323-361-4178 ext 4178    areiff@chla.usc.edu   
Contact: Ana A Cabrera, BA    323 361-4178 ext 4178    ancabrera@chla.usc.edu   
Principal Investigator: Andreas O Reiff, MD         
Sponsors and Collaborators
Children's Hospital Los Angeles
Investigators
Principal Investigator: Andreas Reiff, MD CHLA

Responsible Party: Andreas Reiff MD, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier: NCT01639573     History of Changes
Other Study ID Numbers: CAMPATH-1H SSc
First Posted: July 12, 2012    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018

Keywords provided by Andreas Reiff MD, Children's Hospital Los Angeles:
Patients with Scleroderma

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Connective Tissue Diseases
Skin Diseases
Alemtuzumab
Antineoplastic Agents